Level B· Emerging clinical evidence with positive signalsClinical TrialEurope PMCOpen access

Human umbilical cord mesenchymal stromal cells derivatives in treating diabetic foot ulcers: a phase I/II safety and efficacy trial

Jafar H., Almousa R., Alhawari H., Shahin D., Al Soudi M., Abusharieh E.

Clinical Trial on Type 2 Diabetes, Diabetic Foot, Chronic Wound, published in Stem Cell Res Ther (2025) — summary generated from the PubMed abstract.

Open my reading list
Level B· Emerging clinical evidence with positive signalsEvidence level of this study

Several human studies show positive signals, while research methods and sample sizes continue to develop.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Clinical Trial
Journal
Stem Cell Res Ther (2025)
Reported sample size
—
Source database
Europe PMC
PMID
41287013
PMCID
PMC12642072
DOI
10.1186/s13287-025-04736-1
NCT
NCT06825884

Abstract (original English)

Diabetic foot ulcers (DFUs) are serious and prevalent complications of diabetes mellitus, affecting up to 34% of individuals and contributing substantially to morbidity, healthcare expenditures, and the risk of non-traumatic lower limb amputations. Despite the availability of standard treatment protocols, achieving complete and sustained healing remains a significant clinical challenge. This study investigates the safety and efficacy of allogeneic human umbilical cord mesenchymal stromal cell derivatives (hUC-MSCD), including conditioned media, extracellular vesicles, and exosomes, administered via perilesional injection in patients with chronic DFUs. In this single-center, phase I/II, open-label clinical trial (NCT06825884), ten adult patients (7 males, 3 females; mean age: 52.2 years) with type 2 diabetes mellitus and chronic DFUs classified as Texas Grade II-III (mean ulcer duration: 15 weeks), refractory to standard care, were enrolled. Participants received perilesional injections of allogeneic hUC-MSCD. Safety was evaluated through the monitoring of adverse events, and efficacy was assessed by the rate and duration of ulcer closure, as well as recurrence during follow-up. The intervention was well tolerated, with no significant adverse events observed. All patients achieved complete ulcer closure within a mean of 4.2 weeks (p < 0.00001). Importantly, no ulcer recurrence w

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Several human studies show positive signals, while research methods and sample sizes continue to develop.

How we grade evidence
Mesenchymal Stem CellsUmbilical CordHumansDiabetic FootDiabetes Mellitus, Type 2Treatment OutcomeMesenchymal Stem Cell TransplantationWound HealingAdultAged

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research